コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 Adverse events were reported in 14 patients (67%), with nause
2 Adverse events were reported in 165 (81%) patients in the cla
3 Adverse events were reported in 261 (83%) patients who receiv
4 Adverse events were reported in 74% of patients receiving tha
5 Protocol-specified treatment-related grade
3 adverse events were reported in 7 patients (12.7%; 95% CI, 9.
6 reported in 7 patients (12.7%; 95% CI, 9.6%-15.8%); grade
4 adverse events were reported in 2 patients (3.6%; 95% CI, 2.7
7 Treatment-related grade 3 or
above adverse events were reported in 15 (60%) patients and were ma
8 Treatment-
emergent adverse events were reported in 103 patients (97%), a majorit
9 Treatment-
emergent adverse events were reported in 328 (74%) patients receiving
10 Serious treatment-
emergent adverse events were reported in 7% of patients receiving plac
11 One or more treatment-
emergent adverse events were reported in 78% of patients receiving NTC
12 Moderate treatment-
emergent adverse events were reported in two patients in the brexanolo
13 Deaths
from adverse events were reported in three patients (2%) in the ph
14 Serious drug-
related adverse events were reported in 108 (43%) patients.
15 Drug-
related adverse events were reported in 109 (42%) patients receiving
16 Drug-
related adverse events were reported in 130 (98%) patients assigned r
17 Grade 3 or greater infusion-
related adverse events were reported in 22 (10%) patients given chlor
18 Serious treatment-
related adverse events were reported in five patients (6%): enterocol
19 Serious adverse events were reported in 113 (23%) patients receiving
20 Serious adverse events were reported in 117 (42%) patients in the eve
21 Treatment-related
serious adverse events were reported in 12 (32%) patients in the ipil
22 Serious adverse events were reported in 13 patients (11%).
23 Treatment-related
serious adverse events were reported in 133 (37%) patients in the 10
24 One or more all-causality
serious adverse events were reported in 15 (27%) patients in the axit
25 Serious adverse events were reported in 15 patients (2%) in the sofos
26 Serious adverse events were reported in 17 (8%) patients on romosozum
27 Serious adverse events were reported in 20 (22%) patients; six (7%) w
28 21
serious adverse events were reported in 20 patients during the study,
29 Treatment-related
serious adverse events were reported in 21 (9%) patients given dacomi
30 Any grade of
serious adverse events were reported in 243 (35%) patients.
31 Serious adverse events were reported in 25 (18%) patients who receive
32 Serious adverse events were reported in 25 (9%) patients.
33 Serious adverse events were reported in 25% of patients; seven deaths
34 46
serious adverse events were reported in 27 patients; of 14 suspected
35 Serious adverse events were reported in 3 patients (5%) in the combin
36 Serious adverse events were reported in 358 [46%] patients receiving
37 Serious adverse events were reported in 48 (30%) patients, including
38 Serious adverse events were reported in 52 (12%) patients receiving d
39 Serious adverse events were reported in 52 (25%) patients, of which 1
40 Serious adverse events were reported in eight additional patients in
41 Eight
serious adverse events were reported in eight patients: two were repo
42 Treatment-related
serious adverse events were reported in five patients (11%), all of w
43 Serious adverse events were reported in four (5%) patients given deut
44 11
serious adverse events were reported in seven (25%) patients and incl
45 Serious adverse events were reported in six (10%) patients in the pas
46 Serious adverse events were reported in six patients in the placebo g
47 ]; recurrent cancer of the vulva [grade 4]) and six
serious adverse events were reported in six patients in the treatment
48 Serious adverse events were reported in three (3%) patients who recei
49 Up to week 24,
serious adverse events were reported in three (3%) patients with ixek
50 Thromboembolic adverse events were reported in 153 patients (13.5%) in the d
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。